Krsnaa Diagnostics
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Krsnaa Diagnostics is strategically positioned to leverage India's expanding healthcare diagnostics market, driven by a robust public-private partnership (PPP) model and a growing retail segment. Management's focus on integrating AI technology and optimizing operational costs is expected to enhance revenue visibility, particularly through a significant 30-year partnership that opens high-margin PET-CT services. Despite anticipated short-term margin pressures due to fixed costs associated with new project rollouts, the company's long-term growth strategy aims to capitalize on increasing demand for organized healthcare services. Vista's forecast reflects an acceleration in revenue growth beyond historical trends, supported by the scaling of the Rajasthan PPP project and the expansion of the retail diagnostics network. However, execution risks and regulatory shifts remain critical watchpoints. The healthcare sector's overall growth trajectory, coupled with rising insurance coverage, provides a favorable backdrop, although margin pressures and potential delays in project execution could temper performance. Over the next 12-24 months, Krsnaa's dual-engine growth strategy, focusing on both PPP and retail, positions it well for sustainable growth, with expected upside of approximately 24% from current valuations
Why We Like This Stock
- Strategic 30-year partnership enhances revenue visibility and access to high-margin services
- Expansion of the retail diagnostics network is expected to significantly contribute to revenue growth
- Integration of AI technology is likely to improve operational efficiency and patient throughput
Things To Watch Out For
- Short-term margin pressures due to fixed costs from new project rollouts may impact profitability
- Execution risks related to scaling retail operations and potential delays in project timelines could hinder growth
- Regulatory shifts and administrative delays in government payments pose risks to cash flow and operational stability
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 590 | 682 | 691 | 864 | 1,041 |
| Profit Before Tax (Cr.) | 72 | 105 | 132 | 142 | 178 |
| PBT Margin | 12.2% | 15.5% | 19.1% | 16.5% | 17.1% |
| Net Profit (Cr.) | 61 | 83 | 107 | 116 | 145 |
| Earnings Per Share | 18.7 | 25.7 | 33.1 | 35.6 | 44.7 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Moneycontrol | ▲ Overweight | — | 08-Jul-2026 |
Company Overview
Show Company Profile
Krsnaa Diagnostics Limited provides diagnostic services in India. It offers a range radiology services, including computed tomography scans, magnetic resonance imaging, X-rays, and ultrasound and advanced imaging; pathology services, such as laboratory, and home collection and preventive health; and teleradiology and telepathology services. The company also provides other diagnostics services, such as ophthalmic test, mammography, dental imaging, stress test, dual-energy X-ray absorptiometry scan, and bone mineral density test. It serves individual patients, government clients, corporate clients, hospitals, clinics, private practitioner, and other healthcare providers. Krsnaa Diagnostics Limited was incorporated in 2010 and is based in Pune, India.